Products for Research Use Only
RegisterLogin

Ivonescimab

CAT: 0804-HY-P99675-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99675-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) [1][2][3][4][5].
CAS Number
2428381-53-5
Product Name Alternative
AK112
UNSPSC
12352203
Target
PD-1/PD-L1; VEGFR
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ivonescimab.html
Purity
99.00
Solubility
10 mM in DMSO
Smiles
[Ivonescimab]
Molecular Weight
(201.1 kDa)
References & Citations
[1]Coward J, et al. Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study. Journal for Immuno Therapy of Cancer 2021;9: |[2]Zhong T, et al. AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. Journal for Immuno Therapy of Cancer. 2022;10: |[3]Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. Journal for Immuno Therapy of Cancer. 2022;10:e005517. |[4]Dhillon S. Ivonescimab: First Approval. Drugs. 2024 Sep;84 (9) :1135-1142. |[5]Fang W, et al. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. 2024 Aug 20;332 (7) :561-570.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4

Alternative Products

CatalogName
T77046-01Ivonescimab
GTR18337719-01Ivonescimab Antibody
DHD12605Research Grade Ivonescimab
E55B1285Ivonescimab (Reference antibody)
ICH6015-50mgIvonescimab Biosimilar - Research Grade
GTR18697310-01Ivonescimab Human Monoclonal Antibody
B23603601-01Anti-Human VEGFAxPD-1 (Ivonescimab)
C00918-1mgIvonescimab (Anti-PD-1 & VEGF)
BIO1019SM-1mgAnti-human PD-1 & VEGF (Ivonescimab Biosimilar)
A135533Ivonescimab Biosimilar (Monoclonal, IgG1-kappa-[scFv]2)

Popular Products